drugset / Trial / NCT03440814

A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

NCT03440814

Phase 3 Completed 127 enrolled Soleno Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.

Timeline

Start
2018-05-09
Primary completion
2020-05-01
Completion
2020-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Diazoxide Choline Unknown 75 mg Oral
Subject Diazoxide Choline Unknown 450 mg Oral

Indications